FIELD: medicine.
SUBSTANCE: according to the invention, method involves introduction of Paramycin 42 ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779). In addition, the invention refers to applications of CCI-779 in producing a medicinal agent for amphicyte lymphoma.
EFFECT: application of the invention ensures amphicyte lymphoma treatment.
9 cl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
ANTICANCER COMBINATIONS OF CCI-779 AND RITUXIMAB | 2005 |
|
RU2389508C2 |
ANTI-TUMOR COMPOSITIONS CONTAINING RAPAMICINE DERIVATIVE AND AROMATASE INHIBITOR | 2004 |
|
RU2355399C2 |
ANTICANCER ACTIVITY OF CCI-779 IN PAPILLARY RENAL CELL CARCINOMA | 2008 |
|
RU2501559C2 |
RAPAMYCINE HYDROXY ETHERS-CONTAINING PARENTERAL COMPOSITIONS | 2003 |
|
RU2344821C2 |
ANTI-TUMOUR COMBINATIONS MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2006 |
|
RU2451524C2 |
COMBINATION OF OZOGAMICIN INOTUZUMAB AND TORIZEL FOR TREATING CANCER | 2012 |
|
RU2607594C2 |
ANTITUMOUR COMBINATIONS WITH MTOR INHIBITORS, HERCEPTIN AND/OR HKI-272 | 2012 |
|
RU2632104C2 |
COMBINATION OF PHOSPHATIDYL INOSITOL-3-KINASE (PI3K) INHIBITOR AND mTOR INHIBITOR | 2009 |
|
RU2538683C2 |
LYOPHILISED COMPOSITIONS CCI-779 | 2004 |
|
RU2345772C2 |
USE OF 3-(4-AMINO-1-OXO-1, 3-DIHYDROISOINDOL-2-YL)PIPERIDINE-2,6-DIONE FOR TREATING MANTLE CELL LYMPHOMAS | 2007 |
|
RU2446804C2 |
Authors
Dates
2009-06-20—Published
2004-10-28—Filed